Published in Clin Pharmacokinet on January 01, 2004
Improving Outcomes in Neonatal Abstinence Syndrome | NCT01958476
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA (2013) 2.34
Opioid metabolism. Mayo Clin Proc (2009) 1.76
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 1.72
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Tolerance and withdrawal from prolonged opioid use in critically ill children. Pediatrics (2010) 1.46
Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol (2009) 1.43
Genetic contributions to pain: a review of findings in humans. Oral Dis (2008) 0.96
Role of morphine's metabolites in analgesia: concepts and controversies. AAPS J (2006) 0.91
Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses (2008) 0.89
Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr (2014) 0.88
Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease. J Pediatr Hematol Oncol (2013) 0.88
Tapentadol immediate release: a new treatment option for acute pain management. J Pain Res (2010) 0.87
Prediction of drug response and safety in clinical practice. J Med Toxicol (2012) 0.86
The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol Res Nurs (2012) 0.86
Multiple opioids in pain management. Can Fam Physician (2007) 0.85
Genetic variability of pain perception and treatment--clinical pharmacological implications. Eur J Clin Pharmacol (2011) 0.84
The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity. Pain (2008) 0.83
Buprenorphine in cancer pain. Support Care Cancer (2005) 0.83
Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol (2009) 0.82
Anger regulation style, postoperative pain, and relationship to the A118G mu opioid receptor gene polymorphism: a preliminary study. J Behav Med (2006) 0.82
Limited effects of beta-endorphin compared to loperamide or fentanyl in a neuroendocrine biomarker assay in non-human primates. Psychoneuroendocrinology (2008) 0.81
The role of multidrug resistance-associated protein in the blood-brain barrier and opioid analgesia. Synapse (2013) 0.81
Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend (2015) 0.80
Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap Adv Gastroenterol (2015) 0.79
Different SNP combinations in the GCH1 gene and use of labor analgesia. Mol Pain (2010) 0.78
[Are polymorphisms in the mu-opioid receptor important for opioid therapy?]. Schmerz (2005) 0.78
Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs. Pain Res Treat (2013) 0.77
Improved drug therapy: triangulating phenomics with genomics and metabolomics. Hum Genomics (2014) 0.76
The serotonin transporter gene polymorphism is associated with the susceptibility and the pain severity in idiopathic trigeminal neuralgia patients. J Headache Pain (2014) 0.75
Tramadol overdose and apnea in hospitalized children, a review of 20 cases. Res Pharm Sci (2016) 0.75
Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol (2015) 0.75
From Individualized Treatment of Sickle Cell Pain to Precision Medicine: A 40-Year Journey. J Clin Med Res (2016) 0.75
Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. Semin Perinatol (2016) 0.75
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. Am J Addict (2016) 0.75
CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. Pharmgenomics Pers Med (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
The sequence of the human genome. Science (2001) 101.55
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 8.84
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science (1992) 6.49
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Gender variations in clinical pain experience. Pain (1997) 4.16
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol (1979) 3.78
Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther (1992) 3.58
Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature (1991) 3.46
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet (1995) 3.08
Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature (1982) 2.96
The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet (1989) 2.90
Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain (1999) 2.87
Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol (2001) 2.86
Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci U S A (1993) 2.80
Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther (2001) 2.79
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet (2002) 2.77
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther (1985) 2.69
Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther (2001) 2.62
The control of pain in peripheral tissue by opioids. N Engl J Med (1995) 2.48
Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) (1954) 2.47
Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem (2001) 2.42
Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med (1996) 2.27
An inventory of the human ABC proteins. Biochim Biophys Acta (1999) 2.22
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol (1994) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet (2000) 2.05
Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci (2001) 2.04
Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet (2001) 2.02
Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta (1999) 1.99
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet (2002) 1.96
The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A (1999) 1.96
Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain (1996) 1.95
Antagonism of the analgesic effect of morphine and other drugs by p-chlorophenylalanine, a serotonin depletor. Psychopharmacologia (1968) 1.94
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res (1996) 1.90
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet (1995) 1.89
Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1.80
Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics (2002) 1.79
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet (1999) 1.79
mu-opioid receptor-mediated antinociceptive responses differ in men and women. J Neurosci (2002) 1.77
Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol (1989) 1.73
Isolation and structural organization of the human preproenkephalin gene. Nature (1982) 1.73
Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry (1998) 1.72
Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther (1993) 1.71
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 1.70
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther (1992) 1.66
The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology (2002) 1.66
Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry (1999) 1.66
Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology (1995) 1.66
A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem (2000) 1.65
Identification and characterization of a prostaglandin transporter. Science (1995) 1.65
Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther (2001) 1.65
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics (1998) 1.64
Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther (1989) 1.64
Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther (2000) 1.60
Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry (1999) 1.59
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos (1998) 1.58
The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg (2001) 1.57
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol (2001) 1.57
Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology (2000) 1.55
Heritability of nociception II. 'Types' of nociception revealed by genetic correlation analysis. Pain (1999) 1.53
Polymorphic drug oxidation in humans. Fed Proc (1984) 1.53
Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain (1998) 1.52
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol (2002) 1.52
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics (2001) 1.50
Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol (1996) 1.50
Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol (2000) 1.47
Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther (2000) 1.46
Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther (2002) 1.45
Structural organization of human genomic DNA encoding the pro-opiomelanocortin peptide. Proc Natl Acad Sci U S A (1980) 1.44
Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med (2002) 1.42
Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet (1987) 1.42
Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport (2003) 1.42
The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain (1997) 1.42
The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A (1999) 1.41
Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos (1997) 1.40
Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol (1996) 1.39
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther (1995) 1.38
Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos (1998) 1.35
Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol (1993) 1.34
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 1.33
The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain (1999) 1.33
Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol (2002) 1.32
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem (2001) 1.31
Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum (1999) 1.31
Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther (2003) 1.31
GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med (2006) 3.38
Inhibition of GTP cyclohydrolase attenuates tumor growth by reducing angiogenesis and M2-like polarization of tumor associated macrophages. Int J Cancer (2012) 2.80
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst (2006) 2.51
Pattern of neuropathic pain induced by topical capsaicin application in healthy subjects. Pain (2015) 2.07
Opioids for chronic non-cancer pain. BMJ (2013) 2.07
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1.80
Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66
Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clin Chem (2007) 1.64
Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. J Invest Dermatol (2003) 1.59
Chain length-specific properties of ceramides. Prog Lipid Res (2011) 1.57
No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing. Trends Neurosci (2009) 1.54
Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. Pharmacogenomics (2006) 1.50
COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther (2005) 1.46
Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet (2013) 1.46
Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther (2002) 1.46
Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1-phosphate. Blood (2006) 1.40
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev (2004) 1.40
FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells. J Immunol (2007) 1.38
Epigenetics in pain and analgesia: an imminent research field. Eur J Pain (2010) 1.34
Ziconotide for treatment of severe chronic pain. Lancet (2010) 1.34
Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther (2003) 1.31
Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell (2007) 1.30
The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J (2008) 1.29
Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 1.27
The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics (2006) 1.27
Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain (2008) 1.26
Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci (2004) 1.24
Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques. Am J Psychiatry (2003) 1.21
Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol (2004) 1.21
G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res (2003) 1.20
Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. J Neurosci (2010) 1.19
Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth. Int J Biochem Cell Biol (2012) 1.17
Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer (2009) 1.17
Peripheral opioid analgesia in experimental human pain models. Brain (2003) 1.17
Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis (2009) 1.15
Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med (2005) 1.14
Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation (2008) 1.14
Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J (2006) 1.12
Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens (2009) 1.11
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One (2010) 1.11
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J (2005) 1.10
cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci (2008) 1.10
A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem (2008) 1.10
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenet Genomics (2009) 1.10
FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Mol Immunol (2007) 1.09
Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 1.09
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PLoS One (2010) 1.08
Phenotyping the function of TRPV1-expressing sensory neurons by targeted axonal silencing. J Neurosci (2013) 1.06
PAM mediates sustained inhibition of cAMP signaling by sphingosine-1-phosphate. EMBO J (2004) 1.06
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol (2002) 1.05
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res (2008) 1.04
Sphingosine 1-phosphate modulates spinal nociceptive processing. J Biol Chem (2008) 1.04
Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? Pain (2009) 1.03
5,6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. J Neurosci (2012) 1.03
Cleavage of sphingosine kinase 2 by caspase-1 provokes its release from apoptotic cells. Blood (2010) 1.00
Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis (2003) 1.00
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics (2009) 0.99
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther (2006) 0.99
PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors. Biochem Pharmacol (2007) 0.99
Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol (2008) 0.99
Wound inflammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1 activity in diabetes-impaired wound healing. Diabetes (2005) 0.98
Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol (2010) 0.98
LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples. Prostaglandins Other Lipid Mediat (2006) 0.98
Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. Neurosci Lett (2002) 0.98
Antioxidant activity of sestrin 2 controls neuropathic pain after peripheral nerve injury. Antioxid Redox Signal (2013) 0.98
Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther (2003) 0.97
The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol (2008) 0.97
Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther (2003) 0.97
Current evidence for a modulation of nociception by human genetic polymorphisms. Pain (2007) 0.97
Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. J Biol Chem (2010) 0.97
Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J Neurochem (2002) 0.96
Is mPGES-1 a promising target for pain therapy? Trends Pharmacol Sci (2006) 0.95
Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I. Proc Natl Acad Sci U S A (2004) 0.95
Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet (2006) 0.95
Pharmacogenetics of new analgesics. Br J Pharmacol (2011) 0.95
Genetic modulation of the pharmacological treatment of pain. Pharmacol Ther (2009) 0.94
Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir Ther (2010) 0.94
The ubiquitin ligase MYCBP2 regulates transient receptor potential vanilloid receptor 1 (TRPV1) internalization through inhibition of p38 MAPK signaling. J Biol Chem (2010) 0.93
Protein associated with Myc (PAM) is involved in spinal nociceptive processing. J Neurochem (2004) 0.92
Activation of the AMP-activated protein kinase reduces inflammatory nociception. J Pain (2013) 0.91
Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study. Clin Ther (2007) 0.91
Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol (2006) 0.91
NOXious signaling in pain processing. Pharmacol Ther (2012) 0.90
Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2. FASEB J (2011) 0.90
The calpain inhibitor MDL 28170 prevents inflammation-induced neurofilament light chain breakdown in the spinal cord and reduces thermal hyperalgesia. Pain (2004) 0.90
Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics (2003) 0.90
The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS. Int J Biochem Cell Biol (2013) 0.90
Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injury. PLoS One (2011) 0.90
Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB. Eur J Pharmacol (2006) 0.89
LC-MS/MS-analysis of prostaglandin E2 and D2 in microdialysis samples of rats. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.89
Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J Med Chem (2010) 0.89
Functional genomics of pain in analgesic drug development and therapy. Pharmacol Ther (2013) 0.88
Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation. Mol Pain (2011) 0.88
Antinociceptive activity of the S1P-receptor agonist FTY720. J Cell Mol Med (2008) 0.87
Activation of ceramide synthase 6 by celecoxib leads to a selective induction of C16:0-ceramide. Biochem Pharmacol (2010) 0.87
Comparative proteomic analysis of the rat spinal cord in inflammatory and neuropathic pain models. Neurosci Lett (2005) 0.87